Pfizer, BioNTech Shares Ripe for a Bumpy Ride Ahead of Panel
- FDA panel next week on vaccines is next big catalyst for stock
- Options prices imply outsized moves in the next two weeks
Source: Pfizer Inc.
This article is for subscribers only.
It’s been a wild ride for Pfizer Inc. shares as the S&P 500 heavyweight got caught up in the vaccine-stock euphoria. A key panel next week could mean even more volatility.
A Food and Drug Administration advisory committee meeting scheduled for Dec. 10 is believed to be a means for the agency to assure the public about Covid-19 vaccine safety, and a U.S. emergency use authorization could follow within days.